Contact details:
Qualifications:
MB ChB: University of Pretoria, South Africa, 2001
MRCP (UK): Royal College of Physicians, 2005
PhD Med: University of Manchester, 2011
FRCP (UK): Royal College of Physicians, 2020
Present appointments:
- Consultant Nephrologist, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust: 2013 – present
- Lead on setting up the Health Services Journal award-winning renal Young Adults Clinic at Salford Royal Hospital: 2013 – present
- UK Lead for the Renal Rare Diseases register (RADAR) specialist interest group on FMD: 2016 – present
- NCA Lead for Freedom to Speak up Team, who were finalists in the 2020 Health Services Journal FTSU Organisation of the year: 2016 – present
- Honorary Senior Lecturer in Cardiovascular Sciences, School of Medical Sciences, University of Manchester: 2019 – present
- Sub-group lead on Transition for the Renal Services Transformation Programme and North West Kidney Network: 2021 – present
Previous appointments:
- President Royal Society Medicine, Nephrology Section: 2018 – 2020
Supervision at higher degrees (co-supervisor of one PhD and one MD).
Research interests/expertise:
- Fibromuscular dysplasia (FMD)
- Atheromatous renovascular Disease (ARVD)
- Nephrogenic systemic fibrosis (NSF)
- Glomerulonephritis
Current research grants:
- 21KID03 A Study APOL 1, local Principal Investigator, Medicines Evaluation Unit, Wythenshawe Hospital, (Oct 2020 – end once 500 patients recruited)
- UK FMD Study, Principal Investigator, Northern Care Alliance (November 2022 -November 2032).
Publications (last 5 years):
2023
McDonnell T, Storrar J, Chinnadurai R, Heal C, Chrysochou C, Ritchie J, Rainone F, Poulikakos D, Kalra P, Sinha S, The epidemiology of primary FSGS including cluster analysis over a 20-year period. BMC Nephrol. 2023 Dec 10;24(1):365.
2022
Storrar J, Gill-Taylor T, Chinnadurai R, Chrysochou C, Poulikakos D, Rainone F, Ritchie J, Lamerton E, Kalra PA, Sinha S. A low rate of end-stage kidney disease in membranous nephropathy: A single centre study over 2 decades. PLoS One 2022 Oct 13;17(10):e0276053.
2021
Waldman M, Soler MJ, García-Carro C, Lightstone L, Turner-Stokes T, Griffith M, Torras J, Martinez Valenzuela L, Bestard O, Geddes C, Flossmann O, Budge KL, Cantarelli C, Fiaccadori E, Delsante M, Morales E, Gutierrez E, Niño-Cruz JA, Martinez-Rueda AJ, Comai G, Bini C, La Manna G, Slon MF, Manrique J, Avello A, Fernandez-Prado R, Ortiz A, Marinaki S, Martin Varas CR, Rabasco Ruiz C, Sierra-Carpio M, García-Agudo R, Fernández Juárez G, Hamilton AJ, Bruchfeld A, Chrysochou C, Howard L, Sinha S, Leach T, Agraz Pamplona I, Maggiore U, Cravedi P. COVID-19 in Patients with Glomerular Disease: Follow-Up Results from the IRoc-GN International Registry. Kidney360. 2021 Dec 3;3(2):293-306.
Flouri D, Lesnic D, Chrysochou C, Parikh J, Thelwall P, Sheerin N, Kalra PA, Buckley DL, Sourbron SP. Motion correction of free-breathing magnetic resonance renography using model-driven registration. MAGMA. 2021 Dec;34(6):805-822.
Faconti L, Morselli F, Sinha M, Chrysochou C, Chowienczyk PJ; British and Irish Hypertension Society. Fibromuscular dysplasia and hypertension-a statement on behalf of the British and Irish Hypertension Society. J. Hum. Hypertens. 2021 Nov;35(11):1051-1053.
Persu A, Canning C, Prejbisz A, Dobrowolski P, Amar L, Chrysochou C, Kądziela J, Litwin M, van Twist D, Van der Niepen P, Wuerzner G, de Leeuw P, Azizi M, Januszewicz M, Januszewicz A. Beyond Atherosclerosis and Fibromuscular Dysplasia: Rare Causes of Renovascular Hypertension. Hypertension. 2021 Sep;78(4):898-911.
Chrysochou C, Devresse A, Kanaan N, Persu A. Kidney donors with fibromuscular dysplasia, is it time to open the doors? Nephrol. Dial. Transplant. 2021 Jul 23;36(8):1365-1368.
de Bhailís ÁM, Chrysochou C, Kalra PA. Inflammation and Oxidative Damage in Ischaemic Renal Disease. Antioxidants (Basel). 2021 May 25;10(6):845.
Eddington H, Chinnadurai R, Alderson H, Ibrahim ST, Chrysochou C, Green D, Erekosima I, Hutchison A, Bubtana A, Hegarty J, Kalra PA. A randomised controlled trial to examine the effects of cinacalcet on bone and cardiovascular parameters in haemodialysis patients with advanced secondary hyperparathyroidism. BMC Nephrol. 2021 Mar 23;22(1):106.
Basile C, Davenport A, Mitra S, Pal A, Stamatialis D, Chrysochou C, Kirmizis D.
Frontiers in hemodialysis: Innovations and technological advances. Artif Organs. 2021 Feb;45(2):175-182.
Pappaccogli M, Di Monaco S, Warchoł-Celińska E, Lorthioir A, Amar L, Aparicio LS, Beauloye C, Bruno RM, Chenu P, de Leeuw P, De Backer T, Delmotte P, Dika Z, Gordin D, Heuten H, Iwashima Y, Krzesinski JM, Kroon AA, Mazzolai L, Poch E, Sarafidis P, Seinturier C, Spiering W, Toubiana L, Van der Niepen P, van Twist D, Visonà A, Wautrecht JC, Witowicz H, Xu J, Prejbisz A, Januszewicz A, Azizi M, Persu A; European/International FMD Registry and Initiative (FEIRI), and the Working Group ‘Hypertension and the Kidney’ of the European Society of Hypertension (ESH). The European/International Fibromuscular Dysplasia Registry and Initiative (FEIRI)-clinical phenotypes and their predictors based on a cohort of 1000 patients. Cardiovasc. Res. 2021 Feb 22;117(3):950-959.
Burton JO, Corbett RW, Kalra PA, Vas P, Yiu V, Chrysochou C, Kirmizis D. Recent advances in treatment of haemodialysis. J. R. Soc. Med. 2021 Jan;114(1):30-37.
2020
Lodge MDS, Abeygunaratne T, Alderson H, Ali I, Brown N, Chrysochou C, Donne R, Erekosima I, Evans P, Flanagan E, Gray S, Green D, Hegarty J, Hyde A, Kalra PA, Lamerton E, Lewis D, Middleton R, New D, Nipah R, O’Donoghue D, O’Riordan E, Poulikakos D, Rainone F, Raman M, Ritchie J, Sinha S, Wood G, Tollitt J. Safely reducing haemodialysis frequency during the COVID-19 pandemic. BMC Nephrol. 2020 Dec 7;21(1):532.
2019
Al-Chalabi S, Chrysochou C, Kalra PA. Is it time to relax nephrogenic systemic fibrosis guidelines and safely offer magnetic resonance imaging to more patients? Quant Imaging Med. Surg. 2019 Nov;9(11):1918-1921.
Vassallo D, Alderson H, Vuilleumier N, Ritchie J, Green D, Pagano S, Virzi J, Chrysochou C, Kalra PA. Association of novel biomarkers with major clinical outcomes in a cohort of patients with atherosclerotic renovascular disease. An.n Clin. Biochem. 2019 Jul;56(4):488-501.
Basak S, Buckley DL, Chrysochou C, Banerji A, Vassallo D, Odudu A, Kalra PA, Sourbron SP. Analytical validation of single-kidney glomerular filtration rate and split renal function as measured with magnetic resonance renography. Magn. Reason. Imaging. 2019 Jun;59:53-60.
Green D, Vassallo D, Handley K, Ives N, Wheatley K, Chrysochou C, Hegarty J, Wright J, Moss J, Patel RK, Deighan C, Webster J, Rowe P, Carr S, Cross J, O’Driscoll J, Sharma R, Mark P, Kalra PA. Cardiac structure and function after revascularization versus medical therapy for renal artery stenosis: the ASTRAL heart echocardiographic sub-study. BMC Nephrol. 2019 Jun 14;20(1):220.
Chinnadurai R, Chrysochou C, Kalra PA. Increased Risk for Cardiovascular Events in Patients with Diabetic Kidney Disease and Non-Alcoholic Fatty Liver Disease. Nephron. 2019;141(1):24-30.
2018
Green D, Ritchie JP, Chrysochou C, Kalra PA. Revascularization of atherosclerotic renal artery stenosis for chronic heart failure versus acute pulmonary oedema. Nephrology (Carlton). 2018 May;23(5):411-417.
Vassallo D, Ritchie J, Green D, Chrysochou C, Kalra PA. The effect of revascularization in patients with anatomically significant atherosclerotic renovascular disease presenting with high-risk clinical features. Nephrol. Dial. Transplant. 2018 Mar 1;33(3):497-506.